Today's IPO for Bluejay Diagnostics, Inc. (NASDAQ: BJDX) opened for trading at $5.47 after pricing 2,160,000 units, at a combined price per unit of $10.00.

Dawson James Securities, Inc. and I-Bankers Direct, LLC, acted as joint book running managers for the offering.

Bluejay Diagnostics, Inc. is a late-stage, pre-revenue medical device company focused on improving patient outcomes through the Symphony System, a more cost-effective, rapid, near-patient product candidate for triage, diagnosis and monitoring of disease progression in hospital and long-term acute care (LTAC) settings. Bluejay’s first product candidate, for IL-6 for Sepsis Triage, is designed to provide accurate, reliable results in approximately 24 minutes from ‘Sample-To-Result’ to help medical professionals make earlier and better triage/treatment decisions.